Plasmid DNA for human gene therapy and DNA vaccines. Production and quality assurance.

作者信息

Schorr J, Moritz P, Seddon T, Schleef M

机构信息

QIAGEN GmbH, Hilden, Germany.

出版信息

Ann N Y Acad Sci. 1995 Nov 27;772:271-3. doi: 10.1111/j.1749-6632.1995.tb44757.x.

DOI:10.1111/j.1749-6632.1995.tb44757.x

PMID:8546406

Abstract

摘要

相似文献

Plasmid DNA for human gene therapy and DNA vaccines. Production and quality assurance.

Ann N Y Acad Sci. 1995 Nov 27;772:271-3. doi: 10.1111/j.1749-6632.1995.tb44757.x.

Regulatory issues relating to the use of recombinant vectors in production of human vaccines.

Dev Biol Stand. 1994;82:107-12.

Assessment of adenoviral vector safety and toxicity: report of the National Institutes of Health Recombinant DNA Advisory Committee.腺病毒载体安全性和毒性评估：美国国立卫生研究院重组DNA咨询委员会报告

Hum Gene Ther. 2002 Jan 1;13(1):3-13. doi: 10.1089/10430340152712629.

Purification of plasmids for gene therapy and DNA vaccination.用于基因治疗和DNA疫苗接种的质粒纯化。

Biotechnol Annu Rev. 2001;7:1-30. doi: 10.1016/s1387-2656(01)07031-4.

Characterization of live pseudorabies virus vaccines.

Dev Biol Stand. 1995;84:89-96.

Plasmid DNA for clinical phase I and II studies. Large-scale cGMP manufacturing and quality assurance.用于临床I期和II期研究的质粒DNA。大规模cGMP生产及质量保证。

Adv Exp Med Biol. 1998;451:481-6. doi: 10.1007/978-1-4615-5357-1_74.

Regulatory issues in the use of DNA vaccines.DNA疫苗使用中的监管问题。

Ann N Y Acad Sci. 1995 Nov 27;772:170-7. doi: 10.1111/j.1749-6632.1995.tb44742.x.

Regulating the gene-therapy revolution.规范基因治疗革命。

Nature. 2018 Dec;564(7735):S20-S22. doi: 10.1038/d41586-018-07641-1.

Regulatory aspects of cancer gene therapy and DNA vaccination.癌症基因治疗与DNA疫苗接种的监管方面。

Ernst Schering Res Found Workshop. 2000(30):181-9. doi: 10.1007/978-3-662-04183-3_12.

Recommendations proposed for adenovirus gene therapy trials in the UK.

Mol Med Today. 2000 Dec;6(12):461. doi: 10.1016/s1357-4310(00)01791-3.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验